{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:03:41Z","timestamp":1787241821443,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002101","name":"Division of Health Sciences, University of Otago","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002101","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.bcp.2020.114345","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T21:07:40Z","timestamp":1605906460000},"page":"114345","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["The effect of metformin in EML4-ALK+\u00a0lung cancer alone and in combination with crizotinib in cell and rodent models"],"prefix":"10.1016","volume":"183","author":[{"given":"A.R.","family":"Bland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.L.","family":"Bower","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.J.","family":"Rosengren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2020.114345_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2019.172749","article-title":"Cytotoxicity of curcumin derivatives in ALK positive non-small cell lung cancer","volume":"865","author":"Bland","year":"2019","journal-title":"Eur. J. Pharmacol."},{"issue":"11-12","key":"10.1016\/j.bcp.2020.114345_b0010","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1159\/000506996","article-title":"Does Crizotinib Auto-Inhibit CYP3A in vivo?","volume":"105","author":"Bland","year":"2020","journal-title":"Pharmacology"},{"key":"10.1016\/j.bcp.2020.114345_b0015","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1006\/taap.2001.9170","article-title":"Retinol potentiates acetaminophen-induced hepatotoxicity in the mouse: mechanistic studies","volume":"173","author":"Bray","year":"2001","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114345_b0020","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1158\/0008-5472.CAN-07-6158","article-title":"Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer","volume":"68","author":"Choi","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2020.114345_b0025","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0022-1759(86)90368-6","article-title":"Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability","volume":"89","author":"Denizot","year":"1986","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.bcp.2020.114345_b0030","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.neo.2016.02.001","article-title":"Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells","volume":"18","author":"Dong","year":"2016","journal-title":"Neoplasia"},{"key":"10.1016\/j.bcp.2020.114345_b0035","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00109-014-1165-y","article-title":"Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer","volume":"92","author":"Gower","year":"2014","journal-title":"J. Mol. Med. (Berl)"},{"key":"10.1016\/j.bcp.2020.114345_b0040","first-page":"388","article-title":"Molecular Targets in Non-Small Cell Lung Cancer","volume":"17","author":"Griffin","year":"2017","journal-title":"Ochsner J."},{"key":"10.1016\/j.bcp.2020.114345_b0045","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.107","article-title":"Dose distribution and up-titration patterns of metformin monotherapy in patients with type 2 diabetes","volume":"3","author":"Iglay","year":"2020","journal-title":"Endocrinol. Diabetes Metab."},{"key":"10.1016\/j.bcp.2020.114345_b0050","first-page":"327","article-title":"Global trends of lung cancer mortality and smoking prevalence","volume":"4","author":"Islami","year":"2015","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.bcp.2020.114345_b0055","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3109\/00498254.2014.941964","article-title":"Metabolism, excretion and pharmacokinetics of [14C] crizotinib following oral administration to healthy subjects","volume":"45","author":"Johnson","year":"2015","journal-title":"Xenobiotica"},{"key":"10.1016\/j.bcp.2020.114345_b0060","doi-asserted-by":"crossref","first-page":"7535","DOI":"10.1073\/pnas.1019559108","article-title":"Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK","volume":"108","author":"Katayama","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bcp.2020.114345_b0065","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/j.bcp.2011.08.023","article-title":"Metformin suppresses pregnane X receptor (PXR)-regulated transactivation of CYP3A4 gene","volume":"82","author":"Krausova","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114345_b0070","doi-asserted-by":"crossref","first-page":"34442","DOI":"10.18632\/oncotarget.9120","article-title":"Metformin restores crizotinib sensitivity in crizotinib-resistant human lung cancer cells through inhibition of IGF1-R signaling pathway","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2020.114345_b0075","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.3389\/fphys.2018.01039","article-title":"Molecular Mechanisms of Metformin for Diabetes and Cancer Treatment","volume":"9","author":"Li","year":"2018","journal-title":"Front. Physiol."},{"key":"10.1016\/j.bcp.2020.114345_b0080","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/nm.3667","article-title":"Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer","volume":"20","author":"Lovly","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2020.114345_b0085","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1038\/s41591-018-0125-4","article-title":"Metformin inhibits gluconeogenesis via a redox-dependent mechanism in vivo","volume":"24","author":"Madiraju","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2020.114345_b0090","doi-asserted-by":"crossref","unstructured":"Mathews Samuel S, Satheesh NJ, Ghosh S, B\u00fcsselberg D, Majeed Y, Ding H, et al. (2019). Treatment with a Combination of Metformin and 2-Deoxyglucose Upregulates Thrombospondin-1 in Microvascular Endothelial Cells: Implications in Anti-Angiogenic Cancer Therapy. Cancers (Basel) 11.","DOI":"10.3390\/cancers11111737"},{"key":"10.1016\/j.bcp.2020.114345_b0095","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1158\/1940-6207.CAPR-13-0058-T","article-title":"Inhibition of lung tumorigenesis by metformin is associated with decreased plasma IGF-I and diminished receptor tyrosine kinase signaling","volume":"6","author":"Quinn","year":"2013","journal-title":"Cancer Prev. Res. (Phila)"},{"key":"10.1016\/j.bcp.2020.114345_b0100","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dose translation from animal to human studies revisited","volume":"22","author":"Reagan-Shaw","year":"2008","journal-title":"FASEB J."},{"key":"10.1016\/j.bcp.2020.114345_b0105","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2020.114345_b0110","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/jnci\/82.13.1107","article-title":"New colorimetric cytotoxicity assay for anticancer-drug screening","volume":"82","author":"Skehan","year":"1990","journal-title":"J. Natl Cancer Inst."},{"key":"10.1016\/j.bcp.2020.114345_b0115","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2020.114345_b0120","doi-asserted-by":"crossref","first-page":"35437","DOI":"10.18632\/oncotarget.8881","article-title":"Metformin therapy associated with survival benefit in lung cancer patients with diabetes","volume":"7","author":"Wan","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2020.114345_b0125","doi-asserted-by":"crossref","first-page":"109068","DOI":"10.18632\/oncotarget.22596","article-title":"Metformin sensitizes lung cancer cells to treatment by the tyrosine kinase inhibitor erlotinib","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2020.114345_b0130","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.02242","article-title":"Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis","volume":"3","author":"Wheaton","year":"2014","journal-title":"Elife"},{"key":"10.1016\/j.bcp.2020.114345_b0135","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0026-895X(25)14161-8","article-title":"Demonstration in multiple species of inducible hepatic cytochromes P-450 and their mRNAs related to the glucocorticoid-inducible cytochrome P-450 of the rat","volume":"28","author":"Wrighton","year":"1985","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114345_b0140","doi-asserted-by":"crossref","first-page":"10147","DOI":"10.1038\/srep10147","article-title":"Pharmacologic Therapy of Diabetes and Overall Cancer Risk and Mortality: A Meta-Analysis of 265 Studies","volume":"5","author":"Wu","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2020.114345_b0145","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.3892\/ol.2014.2466","article-title":"Regulation of insulin-like growth factor signaling by metformin in endometrial cancer cells","volume":"8","author":"Xie","year":"2014","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bcp.2020.114345_b0150","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1111\/j.1476-5381.2012.01849.x","article-title":"Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein","volume":"166","author":"Zhou","year":"2012","journal-title":"Br. J. Pharmacol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295220305815?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295220305815?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:23:15Z","timestamp":1757769795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295220305815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":30,"alternative-id":["S0006295220305815"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2020.114345","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of metformin in EML4-ALK+\u00a0lung cancer alone and in combination with crizotinib in cell and rodent models","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2020.114345","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114345"}}